The importance of doing trials right while doing the right trials

Clinical Cancer Research

Volumn 18, Issue 1, 2012, Pages 3-5

  Dilts, David M ^a   Cheng, Steven K ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER INCIDENCE; CANCER RESEARCH; DISEASE SEVERITY; MEDICAL LITERATURE; METHODOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; SAMPLE SIZE;

CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NEOPLASMS; RESEARCH DESIGN;

EID: 84855468385     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2586     Document Type: Article

References (9)

1. Schroen AT, Petroni GR, Wang H, Thielen MJ, Gray R, Benedetti J, et al. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. cooperative oncology groups. Clin Cancer Res 2012;18:256-62.
2. Korn EL, Freidlin B, Mooney M, Abrams JS. Accrual experience of National Cancer Institute cooperative group phase III trials activated from 2000 to 2007. J Clin Oncol 2010;28:5197-201.
3. Cheng SK, DietrichMS, Dilts DM. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clin Cancer Res 2010;16:5557-63.
4. Tam VC, Tannock IF, Massey C, Rauw J, Krzyzanowska MK. Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice. J Clin Oncol 2011;29:3133-9.
5. Ramsey S, Scoggins J. Commentary: practicing on the tip of an information iceberg? Evidence of underpublication of registered clinical trials in oncology. Oncologist 2008;13:925-9.
6. National Cancer Institute. Report of the Operational Efficiency Working Group of the Clinical Trials and Translational Research Advisory Committee, Compressing the Timeline for Cancer Clinical Trial Activation. March 2010. Available from: http://ccct.cancer.gov/files/OEWG-Report.pdf
7. Institute of Medicine. A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. Washington, DC: Institute of Medicine of the National Academies; 2010.
8. Wheelwright SC, Clark KB. Revolutionizing product development: quantum leaps in speed, efficiency, and quality. New York: Free Press; 1992.
9. Dilts DM, Sandler AB. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol 2006;24:4545-52. (Pubitemid 46630949)